Article
HIV-1 reverse transcriptase and protease resistance mutations selected during 16-72 weeks of therapy in isolates from antiretroviral therapy-experienced patients receiving abacavir/efavirenz/amprenavir in the CNA2007 study.
Antiviral therapy - 1 Apr 2003
Ait-Khaled Mounir, Rakik Abdelrahim, Griffin Philip, Stone Chris, Richards Naomi, Thomas Deborah, Falloon Judith, Tisdale Margaret
Abstract excerpt
OBJECTIVE: To determine HIV-1 reverse transcriptase (RT) and protease (PRO) mutations selected in isolates from antiretroviral therapy (ART)-experienced patients receiving an efavirenz/abacavir/amprenavir salvage regimen. METHODS: Open-label, single arm of abacavir, 300 mg twice daily, amprenavir, 1200 mg twice daily and efavirenz, 600 mg once daily, in ART-experienced patients of which 42% were non-nucleoside...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.